• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

PRODUCT FILTERS

REGION

142
20
13
13
11

COUNTRY

6
4
4
4
3

PRICE

86
117
292
517

PUBLISHED

2
15
138
517

PRODUCT TYPE

511
3
2
1

Immune Disorders

(517 Products)

More than 150 primary immunodeficiency diseases (PIDs) have been identified, a number that does not include acquired immunodeficiencies. Examples of immune disorders include Type 1 diabetes, rheumatoid arthritis, allergies, Crohn’s Disease, and HIV, which infects over 0.5% of the world’s population.

In the reports and subscriptions listed under Research and Markets’ category you will find pipeline assessments of drugs and therapeutics, market forecasts, investment and growth opportunities, and much more. Also explored in-depth is the key role of immune response and pharmaceuticals in transplant medicine, with reviews of clinical trials, market trends and major companies in the areas of lung transplants, liver transplants, transplant inflammation/rejection, etc.

Key players profiled include Abbott Laboratories, Pfizer, Johnson & Johnson, Biogen Idec, Amgen, Bayer AG, Sanofi, and more. Show Less
Read more

Triple Analysis: Apoptosis, Angiogenesis and Peptides

This triple analysis focuses on cancer drug development strategies by the two mechanism/target/effect areas of Apoptosis and Angiogenesis and by the compound strategy of Peptides. Each of these three...

January 2013
FROM

Triple Analysis: Apoptosis, Antibodies and Peptides

This triple analysis focuses on cancer drug development strategies by the mechanism/target/effect of Apoptosis and by the two compound strategies of Antibodies and Peptides. Each of these three individual...

January 2013
FROM

Triple Analysis: Breast Cancer, Apoptosis and Peptides

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Breast Cancer), one mechanism/target/effect area (Apoptosis) and one compound specific area (Peptides)....

January 2013
FROM

Triple Analysis: Lung Cancer, Apoptosis and Peptides

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Lung Cancer), one mechanism/target/effect area (Apoptosis) and one compound specific area (Peptides)....

January 2013
FROM

Triple Analysis: Apoptosis, Protein Kinase Inhibitors and Peptides

This triple analysis focuses on cancer drug development strategies by the two mechanism/target/effect areas of Apoptosis and Protein Kinase Inhibitors and by the compound strategy of Peptides. Each...

January 2013
FROM

EpiCast Report: Human Immunodeficiency Virus - Epidemiology Forecast to 2022

EpiCast Report: Human Immunodeficiency Virus - Epidemiology Forecast to 2022 Summary Human immunodeficiency virus (HIV) is a retrovirus that infects cells of the immune system, destroying or impairing...

December 2012
FROM

Von Hippel-Lindau Syndrome - Pipeline Review, H2 2012

Von Hippel-Lindau Syndrome – Pipeline Review, H2 2012 Summary Global Markets Direct’s, 'Von Hippel-Lindau Syndrome - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic...

December 2012
FROM

Inflammation - Pipeline Review, H2 2012

Inflammation – Pipeline Review, H2 2012 Summary Global Markets Direct’s, 'Inflammation - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides...

December 2012
FROM

Cedar Pollen Allergy - Pipeline Review, H2 2012

Cedar Pollen Allergy – Pipeline Review, H2 2012 Summary Global Markets Direct’s, 'Cedar Pollen Allergy - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This...

December 2012
FROM

Food Allergy - Pipeline Review, H2 2012

Food Allergy – Pipeline Review, H2 2012 Summary Global Markets Direct's, 'Food Allergy - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline This report provides...

December 2012
FROM

Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) - Pipeline Review, H2 2012

Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) – Pipeline Review, H2 2012 Summary Global Markets Direct’s, 'Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid...

December 2012
FROM

Pemphigus Vulgaris - Pipeline Review, H2 2012

Pemphigus Vulgaris – Pipeline Review, H2 2012 Summary Global Markets Direct’s, 'Pemphigus Vulgaris - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This...

December 2012
FROM

Xeljanz (tofacitinib) (Rheumatoid Arthritis) Forecast and Market Analysis

Xeljanz (tofacitinib) (Rheumatoid Arthritis) Forecast and Market Analysis Summary GlobalData has released its new PharmaPoint Drug Evaluation report, Xeljanz (tofacitinib) (Rheumatoid Arthritis) Forecast...

November 2012
FROM

Sirukumab (Rheumatoid Arthritis) Forecast and Market Analysis

Sirukumab (Rheumatoid Arthritis) Forecast and Market Analysis Summary GlobalData has released its new PharmaPoint Drug Evaluation report, Sirukumab (Rheumatoid Arthritis) Forecast and Market Analysis....

November 2012
FROM

Simponi (Rheumatoid Arthritis) Forecast and Market Analysis

Simponi (Rheumatoid Arthritis) Forecast and Market Analysis Summary GlobalData has released its new PharmaPoint Drug Evaluation report, Simponi (Rheumatoid Arthritis) Forecast and Market Analysis....

November 2012
FROM

Secukinumab (Rheumatoid Arthritis) Forecast and Market Analysis

Secukinumab (Rheumatoid Arthritis) Forecast and Market Analysis Summary GlobalData has released its new PharmaPoint Drug Evaluation report, Secukinumab (Rheumatoid Arthritis) Forecast and Market Analysis....

November 2012
FROM

Remicade (Rheumatoid Arthritis) Forecast and Market Analysis

The RA market is currently very dynamic, with the November 6, 2012 FDA approval of Pfizer's Xeljanz (tofacitinib) and novel oral therapies awaiting approval such as: Eli Lilly's anti-BAFF, tabalumab...

November 2012
FROM

Rituxan (Rheumatoid Arthritis) Forecast and Market Analysis

Rituxan (Rheumatoid Arthritis) Forecast and Market Analysis Summary GlobalData has released its new PharmaPoint Drug Evaluation report, Rituxan (Rheumatoid Arthritis) Forecast and Market Analysis....

November 2012
FROM

Baricitinib (Rheumatoid Arthritis) Forecast and Market Analysis

Baricitinib (Rheumatoid Arthritis) Forecast and Market Analysis Summary GlobalData has released its new PharmaPoint Drug Evaluation report, Baricitinib (Rheumatoid Arthritis) Forecast and Market Analysis....

November 2012
FROM

Sarilumab (Rheumatoid Arthritis) Forecast and Market Analysis

Sarilumab (Rheumatoid Arthritis) Forecast and Market Analysis Summary GlobalData has released its new PharmaPoint Drug Evaluation report, Sarilumab (Rheumatoid Arthritis) Forecast and Market Analysis....

November 2012
FROM
Loading Indicator

Our Clients

Merck & Co., Inc. Celgene Corporation GlaxoSmithKline PLC Genentech, Inc. Johnson & Johnson Services, Inc. ViiV Healthcare